Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $195.08.

JAZZ has been the subject of a number of recent research reports. Barclays dropped their target price on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, March 1st. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. UBS Group dropped their target price on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research report on Friday, March 1st. HC Wainwright dropped their target price on Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating for the company in a research report on Thursday, March 14th. Finally, Piper Sandler upped their price objective on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $109.46 on Friday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24. The firm has a market cap of $6.90 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.48 and a beta of 0.59. The business’s fifty day moving average is $118.25 and its two-hundred day moving average is $121.75. Jazz Pharmaceuticals has a 52 week low of $106.61 and a 52 week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. Equities research analysts forecast that Jazz Pharmaceuticals will post 16.24 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Rise Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares during the last quarter. Cape Investment Advisory Inc. raised its holdings in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after acquiring an additional 292 shares in the last quarter. Covestor Ltd raised its holdings in Jazz Pharmaceuticals by 676.5% in the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after acquiring an additional 345 shares in the last quarter. Assetmark Inc. raised its holdings in Jazz Pharmaceuticals by 37.1% in the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 119 shares in the last quarter. Finally, Spire Wealth Management raised its holdings in Jazz Pharmaceuticals by 128.6% in the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 238 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.